The milestone progress has been made in the joint development of whole human GPCR antibody drugs by baicalto and liberothera

2021 year 2 month 1 Japan , Baccetus （ Beijing ） Pharmaceutical Technology Co., Ltd （“ Baccetus ”） With Japan LiberoThera Co., LTD. （“LiberoThera”） Announce jointly , Based on the advanced human antibody mice in the world RenMab? Antibody discovery platform and LiberoThera Excellent membrane protein antigen preparation technology , The two sides jointly carry out the whole person GPCR Strategic cooperation in antibody development . In just one year or so since the cooperation was reached , Both sides have targeted the first cooperation target CCR8, Several human therapeutic antibody clones with excellent antitumor activity in vitro and in vivo were screened , It has the potential to become the best product of its kind . These clones have high affinity for human CCR8 And can cross identify across species , Simple production process and other excellent characteristics . On mechanism , These clones are available through enhanced ADCC Effect to deplete the tumor microenvironment Treg, It can also be achieved by inhibiting its ligand CCL1 Mediated CCR8 Signal pathways to inhibit Treg activity , So as to enhance the anti-tumor immune response . future , The cooperation between the two sides will also be extended to other GPCR Target point .

GPCR It's seven transmembrane proteins , The extracellular region is short , Different GPCR High homology between , Therefore, it is difficult to find highly specific , Antibody with target function . Target knockout of whole human antibody mice based on the biota RenMab KO、 A variety of immune and antibody discovery techniques and high-throughput in vitro and in vivo screening platforms , as well as LiberoThera Yes GPCR In depth understanding of target structure and membrane antigen preparation technology ,GPCR The success rate and speed of antibody discovery have greatly increased .

The founder of 100 Olympic Games 、 The chairman and CEO Dr. shenyuelei said ：“ I'm glad to be with LiberoThera Under the joint efforts of , Potential targets for tumor immunotherapy CCR8 The development of drugs is progressing smoothly . This undoubtedly confirms LiberoThera Advanced antigen preparation technology and our RenMice KO The platform is strong and strong , It can promote the production of diverse human antibodies . Combined with the high-throughput in vivo and in vitro screening ability of bacetaxel , Can be effectively obtained for GPCR Effective antibody . We are looking forward to CCR8 The antibody can be advanced to clinic as soon as possible , Also looking forward to working with LiberoThera Jointly conquer more GPCR Target point .”

LiberoThera The company's CEO Toru Kanke Doctor said ,“ many GPCR It is an important drug target for a variety of indications , However, due to the special structure of this kind of target , The development of antibody drugs against them has been facing challenges . use LiberoThera Its own cell-free membrane synthesis technology and the preparation of unnatural amino acid incorporation method GPCR Structural antigens provide a solution for the production of high-quality antibodies against challenging targets . The integrated whole human antibody development platform of baicalto has greatly accelerated the development of GPCR Transformation of target research . We are glad to see the rapid progress of bilateral cooperation , And found that for CCR8 Best in class therapeutic antibody . We also look forward to the future cooperation with b.o.saitu to rapidly promote multiple targets , open GPCR The new situation of antibody research , For the benefit of patients around the world .”

About the hundred Olympic Games GPCR Antibody discovery platform

GPCR (G protein-coupled receptor) Protein is the largest membrane protein in the human genome . Among the drugs on the market , Yes 1/3 The drug acts on GPCR protein . in the light of GPCR Antibody drugs can not only activate or block GPCR Signal path , It can also be through antibody ADCC or ADCP Equal effect directly targets and destroys diseased cells . However , Because antigen preparation is difficult 、 Lack of high-throughput screening methods and other reasons ,GPCR Antibody development faces great challenges , What is found at present GPCR But the target of the patent medicine is 370 individual , But only 2 A ready-made medicine , A lot of valuable GPCR The target remains to be excavated .

In order to improve the target GPCR The success rate of antibody discovery , Hundred Olympic Games has now established a perfect GPCR Antibody discovery platform . Through a variety of GPCR antigen , Such as DNA antigen , To immune target gene knockout RenMiceTM rat （RenMice KO）, Directly obtain the whole human antibody against this target . This not only eliminates the time for humanization of antibodies , It also avoids the reduction of antibody affinity in the process of humanization ; meanwhile , The target knockout mouse has released its pair GPCR Immune tolerance of the target , Therefore, antibodies with more epitopes can be produced after immunization , Improve the success rate of subsequent antibody discovery , It also improves the possibility of finding cross recognition antibodies of multiple species , It is conducive to the subsequent in vivo efficacy verification 、 Safety evaluation and clinical transformation .

Combined with its own based on Beacon High throughput antibody screening platform , It can quickly screen the whole person with high specificity and high affinity GPCR antibody . Report cell lines and humanized mice through self built gene editing , It can carry out large-scale in vitro and in vivo pharmacodynamic analysis , Realization GPCR A large number of antibody drugs 、 Quickly found .

at present , in the light of GPCR Target point , Baccetus “ Thousands of mice fight against it ” Several projects are planned to start , Covering monoclonal antibodies 、 Double antibody and other drug forms , For the treatment of tumors 、 Metabolic diseases . at present ,ADGRE1,C5AR1,CCR9,CXCR4, GPRC5D etc. 15 Targets have been combined GPCR Antibody sequence of , More targets are being explored . B & s hopes to work with global partners to promote targeted GPCR And other valuable difficult target antibody drug development , Continue to produce new drugs , Benefit patients .

About the hundred Olympic Games

Besto is an international biopharmaceutical company with innovative technology driving the research and development of new drugs , We are committed to becoming the birthplace of new drugs in the world , Focus on technological innovation 、 Continuous new drug output 、 Protecting human health is our mission . Based on the self-developed whole human antibody with completely independent intellectual property rights RenMiceTM platform （RenMab? and RenLite? Mice ）, Develop the technology platform of monoclonal antibody and double antibody 、 Animal in vivo drug efficacy screening platform 、 Strong clinical development capabilities are organically integrated , Formed a unique 、 New drug research and development capability covering the whole process of drug research and development .

Hundred orsetto is right 1000 Carry out large-scale drug development with multiple potential drug targets （“ Thousands of mice fight against it TM” plan ）, With the implementation of the plan , Hundred Olympic Games has signed 24 A drug cooperative development agreement has been signed with many MNC Inside 14 Enterprises reached RenMiceTM Platform authorization cooperation . The company has now established 12 Core drug product pipeline , among 2 Products in international Multi Center （MRCT） Clinical trials II period ,2 In clinical trials I period . future , We will continue to work with our global partners , Continuous output is numerous first-in-class and best-in-class Antibody drugs , Better benefit patients . The headquarters of the company is located in Beijing , In Haimen, Jiangsu 、 Shanghai 、 Boston in the United States and Heidelberg in Germany have branches .